Mylan launches generic Felbatol

PITTSBURGH — Mylan announced Tuesday that it had launched its generic of Felbatol (felbamate) tablets after receiving approval from the Food and Drug Administration. 

 

The drug, which Mylan has made available in 400- and 600-mg dosage strengths, is indicated to treat partial seizures without generalization as adjunctive therapy or monotherapy in epileptic adults and to treat partial and generalized seizures due to Lennox-Gastaut syndrome in children. 

 

The drug had U.S sales of about $53 million for the 12 months ended Nov. 30, 2015, according to IMS Health.